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Summary 
 
Mental health and substance use disorders are the leading cause of long term disability and 
a cause of significant mortality, worldwide.  However, it is widely recognised that clinical 
practice in psychiatry has not fundamentally changed for over half a century.  The Royal 
College of Psychiatrists is reviewing its trainee curriculum to identify neuroscience that 
relates to psychiatric practice.  To date though, neuroscience has had very little impact on 
routine clinical practice.  We discuss how a pragmatic approach to neuroscience can address 
this problem together with a route to implementation in NHS care.  This has implications for 
altered funding priorities and training future psychiatrists.  Five training recommendations 
for psychiatrists are identified. 
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Introduction 
There is a remarkable need for progress in the practice of clinical psychiatry.  Mental illness 
and substance use disorders are the leading cause of disability world-wide with major 
depressive disorder (MDD) the commonest cause,
1, 2
 suicide is a leading cause of death in 
young adults,
2
 and severe and enduring mental illness is associated with a reduction in 
lifespan of about a decade.
3
  However, it is widely recognised that clinical practice in 
psychiatry has not fundamentally changed for over half a century.
4, 5
  
      During this time neuroscience has developed a range of sophisticated techniques 
allowing brain structure and function to be non-invasively investigated in unprecedented 
ways.
6
  Magnetic Resonance Imaging (MRI) allows non-invasive mapping of brain structure 
and function (fMRI), Magnetoencephalography (MEG) allows mapping of magnetic fields 
occurring naturally in the brain complementing Electroencephalography (EEG), and Positron 
Emission Tomography (PET) allows mapping of neurotransmitters.  Countless neuroimaging 
studies have reported statistically significant differences between groups of patients and 
healthy controls and findings from ever larger molecular genetics studies are being 
reported.  However, despite this incredible scientific and methodological advance, no 
progress has been made in applying neuroscience pragmatically to psychiatry.  
      Responding to this need, the goal of pragmatic psychiatric neuroscience
7
 is to develop 
neuroscience-based objective quantitative markers that aid clinical decision-making and 
have implications for individual patients: e.g. by objectifying diagnosis, quantifying 
prognosis, supporting treatment selection and yielding objective severity markers for 
disease monitoring.  For example, it can often take months or years of trying different 
antidepressants to find one that is effective (if any) for a particular patient. There is good 
evidence for some antidepressants being more effective and tolerable than others,
8
  yet 
different patients respond to different antidepressants without a clinically obvious pattern.
9
  
We  would like to be able to say, “Mrs Smith, your depression test has come back and with 
this particular antidepressant, you have a 90% chance of being symptom free in six 
weeks”.
10
 
 
Traditional Group-Level Statistical Significance Framework 
There are various reasons for the limited impact of neuroscience on clinical psychiatry. 
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      First, reproducibility of research findings has been a problem.
11
 Only recently have very 
large sample sizes become available to provide definitive group-level results: e.g., the 
ENIGMA Consortium recently reported a meta-analysis of structural brain scans from 8,921 
MDD patients and controls from sites worldwide.
12
  Patients had significantly lower 
hippocampal volumes with the authors concluding their study robustly identified 
hippocampal volume reductions in MDD.
12
  This is a definitive result however it is not 
clinically useful for individual patient management, as will be discussed.  Far larger 
psychiatric genetics studies typically failed to identify significant findings, although a recent 
study with 480,359 MDD participants and controls did report significant findings.
13
 Very 
small genetics effect sizes are unlikely to be useful for decision making with individual 
patients; a different statistical framework is required.
14, 15
 
      Second, psychiatric disorders are fundamentally multivariate constructs.  When taking a 
psychiatric history and conducting a mental state examination, multiple symptom and social 
areas are explored before decision making such as diagnosis and treatment selection.  
Therefore it should not be surprising that a single univariate measure, such as a single 
interview question, hippocampal volume or a single genetic measure is insufficient to 
substitute for this.  Indeed the National Institute of Mental Health, Research Domain Criteria 
(RDoC), currently has five domains of human function within which there are multiple ‘units 
of analyses’.
16, 17
 
      The main problem with a group level statistical significance framework is that it only 
allows inferences about group differences (e.g. average hippocampal volume in MDD vs. 
controls) and not individual patients.  Using this approach with psychiatric disorders, there is 
invariably substantial overlap in the distribution of a single variable for individual patients 
and controls, meaning that if such a measure is used in an attempt to make a clinically 
relevant prediction for an individual patient, the predictive accuracy is so low as to be 
clinically useless (Fig. 1 (a)).  No increase in study size will change this and no single measure 
has ever been identified which is clinically useful.  Group level statistical significance is not 
the same as individual patient clinical significance. 
 
Alternative Individual-Patient Pragmatic Risk-Prediction Framework 
A multivariate risk-prediction framework may provide a better approach to generate 
clinically useful predictions about individual patients. 
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      Strengths of this approach include not being dependent on first understanding 
psychiatric nosology which is controversial and not requiring formulation of illness 
‘mechanisms’ which are yet to be identified.  Instead it uses predictors (covariates) to 
estimate the absolute probability or risk that a certain outcome is present (diagnostic) or 
will occur within a specific period (prognostic) in an individual with a particular predictor 
profile, so having an immediate impact on clinical practice.
10
 Further strengths of this 
approach are a clear utilitarian approach, sound statistical basis, a framework for iterative 
improvement and compatibility with a mechanistic understanding of psychiatric disease.
7
  
This type of approach is already used in other areas of medicine: e.g. risk calculators for 
predicting an individual patient’s risk of a vascular event or cancer within a given period. 
     Different computational methods can be used to implement a risk-prediction framework:  
‘machine learning’ is a collective term for a set of methods which can be used to train a 
predictor to make individual patient predictions.  At its simplest, a sample of data is split 
into two parts and one part used to train a predictor with the other part of the data, which 
has not been used for training, used to test the predictive accuracy, sensitivity and 
specificity.  This is cross-validation, also known as within-study replication.  The testing data 
is equivalent to data from newly presented patients we want to make predictions for.  
Crucially, even when the distributions of individual variables strongly overlap, it’s possible 
for a machine learning approach to make accurate individual patient predictions (Fig. 1 (b)). 
 
Proof of Concept Studies for Individual Patient Prediction 
Prediction methods require quantitative data and these vary in terms of objectivity, 
practicality and accessibility to routine clinical services.  Subjective quantitative data can 
easily be generated from clinical rating scales, e.g. Hamilton Depression Rating Scale.
18
 
These are subjective because patients are asked to match the way they have been feeling to 
a choice of different statements.  There are recent NHS initiatives to record subjective data 
for individual patients, such as brief symptom measures acquired as part of the Improving 
Access to Psychological Therapies (IAPT) in England.
19
  Rating scales with machine learning 
have been used to discover subtle patterns of differential treatment response,
20, 21
  although 
more objective measures might be more reliable predictors and provide better insight into 
abnormal biology. 
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      Objective data includes items such as age and gender but are of limited use because they 
contain little information.  The most readily available ‘information rich’ source of data is 
likely a T1-weighted MRI brain ‘structure’ scan.  It is objective because it requires no 
subjective judgement by a patient and minimal co-operation (lying still).  It is practical 
because it takes ~ 4 minutes to acquire and readily available because all NHS radiology 
departments with an MRI scanner can acquire such data without extra equipment.  We 
provide a few examples of ‘proof of concept’ studies that provide cross-validation estimates 
for individual patient predictions.  If useful for routine clinical practice, further work would 
be required to develop the technique for an NHS environment. 
 
Example 1: Prediction of MDD Diagnosis and Illness Severity 
A multi-centre study tested if it was possible to make an accurate diagnosis of MDD for 
individual patients using only T1-weighted brain ‘structure’ scans.
22
  A machine learning 
technique was used and a high diagnostic prediction accuracy of ~90% for individual 
patients was reported.  An independent study
23
 reported 85% accuracy of individual patient 
diagnostic prediction, and using fMRI data, 97% cross-validation diagnostic accuracy.
24
   
Successful prediction of MDD illness severity using T1 brain ‘structure’ scans has also been 
reported.
25
 
 
Example 2: Prediction of Drug-Relapse for Abstinent Methamphetamine Users 
Accurate prediction of relapse for currently abstinent previously drug misusing patients is 
not possible using standard clinical measures.
7
  Fifty-eight methamphetamine dependent 
patients were recruited from an inpatient treatment program and participated in a stop-
signal task during fMRI.   These patients were prospectively followed for a year then 
reassessed.  Using fMRI measures of brain activity in combination with a computational 
model of behaviour and brain activity, relapse was predicted with accuracy ~78% using  
cross-validation.
7
 
 
Example 3: Prediction of CBT Outcome for Anxiety Disorders  
It is difficult to accurately predict outcome of Cognitive Behavioural Therapy (CBT) and such 
treatment requires access to extended therapist time which is expensive.  Before receiving 
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CBT, adults with Generalised Anxiety Disorder or Panic Disorder took part in an emotional 
regulation task during fMRI.
26
  Standard clinical and demographic variables predicted 
individual patient clinical outcome with 69% accuracy: fMRI measures predicted individual 
clinical outcome more accurately at 79%.
26
 
 
Example 4: Prediction of Antidepressant Outcome for Depression 
There is no empirically validated method to determine whether a patient will respond to a 
specific antidepressant.  Using STAR*D ratings and a machine learning approach it was 
possible to predict individual patient symptomatic remission from a 12 week course of 
citalopram with 60% accuracy.
21
 The predictive model was validated in an independent 
sample of escitalopram treated patients.  Further development of predictive techniques to 
select the best antidepressant for individual patients with MDD would be beneficial.  This 
could be achieved by: i) including a larger numbers of questionnaires than STAR*D  to 
identify a better list of questions and ii) use of EEG/MRI measures which are likely to be 
useful for predicting antidepressant response.
27
 
 
Example 5: Prediction of Dementia and predictions for Non-Psychiatric Disease 
Predicting the risk of dementia for patients presenting with mild cognitive impairment (MCI) 
is important clinically as it would i) facilitate already available preventative interventions for 
vascular disease (vascular dementia) and ii) for Alzheimer’s disease allow recruitment into 
clinical trials of novel medications for patients who do not have advanced disease.  Proof of 
concept studies have been published for some time: e.g. Zhang reported 78% accuracy of 
dementia diagnosis at least 6 months ahead of baseline scanning.
28
  Commercial interest in 
predictive healthcare computing in non-psychiatric areas is booming: e.g. Google 
DeepMind’s partnership with the Royal Free London NHS Foundation Trust (acute kidney 
injury detection) and with UCL hospitals (head/neck cancer and retinal imaging at 
Moorfields). 
 
Summary: These examples show that using a predictive framework with neuroscience 
techniques, it is possible to make objective clinically useful predictions for individual 
patients:  diagnoses, illness severity, drug abstinence relapse, psychotherapy and 
medication treatment outcomes.  It is important to note that machine learning, like any 
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technique, can be misapplied so care is needed in its use.
29-32
   Crucially: i) samples need to 
be representative of the NHS populations of interest, ii) calculations need to be properly 
cross-validated and tested against independent samples, iii) different machine learning 
methods should be compared and iv) careful analyses need be done to determine whether 
there are hidden confounders (e.g. artefacts) driving what the algorithms use to predict. 
    The ultimate aim of these multivariate approaches is to optimize individual patient care.  
This means a series of studies are required, starting with relatively inexpensive single 
studies correctly using cross-validation, then more expensive larger replication studies with 
independent data, then prospective clinical trials as part of NHS care.  There are some 
initiatives, e.g. patients with first episode psychosis in South London and Maudsley NHS 
Trust are being assessed using neuroimaging and blood tests as such measures may allow 
prediction of antipsychotic response.
33, 34
  In addition, these predictive approaches can also 
be used to aid illness mechanisms research: it’s possible to examine the neurobiological 
differences between those individuals who were successfully predicted to respond to a 
treatment versus those that were successfully predicted to not respond to a particular 
treatment.  However, to date, no predictive technique for psychiatry is under development 
in an NHS environment.  NHS implementation issues will now be considered. 
 
Implementation in the NHS 
It seems inevitable that machine learning based techniques will start to be introduced into 
non-psychiatric areas of NHS health care before long: e.g. researchers at John Radcliffe 
Hospital in Oxford have developed a machine learning technique for cardiac scans which 
greatly outperformed Consultants.  The route to adoption of new NHS technologies in the 
UK is well established, first by establishing sufficient evidence for the benefit of the 
intervention by suitable clinical trials and economic studies of cost feasibility, then 
assessment of a sufficient level of cost-benefit evidence by the National Institute of Health 
and Care Excellence (NICE), then recommendation by NICE of adoption by the NHS and 
finally implementation by the NHS.  However, adoption of new techniques is challenging 
because of the UK government’s ‘austerity’ fiscal policy which restricts spending for routine 
NHS care and other public sector areas and which has been in place for a decade. 
      The route to NHS implementation of predictive techniques for psychiatric disorders is 
not fundamentally different; however, there are additional barriers.  Quantitative data is 
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required and can be readily generated, but NHS psychiatric services routinely collect very 
little quantitative data relevant for individual patients.  Only old age patients presenting 
with Mild Cognitive Impairment routinely receive an MRI scan as part of assessment.  Even 
for patients presenting with MDD, it is not part of routine practice in General Adult 
Psychiatry to quantify illness severity using an established rating scale despite e.g. the 
Hamilton Depression rating scale being available since 1960
18
 although brief symptom 
measure collection is increasing with IAPT.  Instead the UK focus remains qualitative clinical 
impressions, social interventions and health service reorganisation.  Without a change in 
culture, significant clinical progress seems unlikely. 
 
UK Stakeholders, Funding and Psychiatric R&D 
UK stakeholders are patients with mental illness and addictions, their families and politically 
influential organisations representing them.  Individual patients are often very supportive of 
biomedical research into mental illness and addictions, which has allowed recruitment of 
vast genetics studies and huge neuroimaging studies.  However psychiatry is unique as a 
medical speciality in having a section of society opposed to a biomedical approach plus 
CMHT staff do not always accept that mental illness has a biological component.  Other than 
the newly emerged MQ charity, there are no UK mental health charities supportive of 
biomedical R&D.  The MRC, Wellcome Trust and NIHR support biomedical research into 
psychiatric disorders.  However only ¬5% of total UK medical funding is spent on mental 
illness
35
 and a small number of London Universities, Oxford and Cambridge receive ~46% of 
all UK public and charity funding,
36
  meaning funding is very limited in most parts of the UK.  
In contrast, patients with dementia and their charities strongly support biomedical research 
and funding is far higher.
35
  Therefore, whilst large numbers of individual patients support 
biomedical R&D into mental illness and addictions, currently, UK progress in this clinical field 
is likely to be limited. 
 
Recommendations for Training Future Psychiatrists 
i) It is important for future psychiatrists to understand the value of quantifying clinically 
relevant aspects of illness, starting by using clinical rating scales and gaining experience in 
their use.  The objective is not to replace qualitative judgement, but to supplement it as is 
routine in other areas of medicine. 
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ii) It is crucial for psychiatrists to be able to differentiate statistical significance from 
clinically meaningful measures useful for individual patient care. 
iii) It is helpful to be familiar with RDoC domain constructs and reflect on how psychiatric 
symptoms for individual patients relate to these: negative and positive valence systems, 
cognitive systems, social processes and arousal-regulatory systems.
16
 
iv) Learning how to synthesise information across ‘units of analyses’ is important (e.g. 
symptoms, behaviour, brain circuits and molecular findings)
16
 and will help avoid the 
outdated ‘biology vs psychology’ philosophical dichotomy.
17
 
v) To gain entry to medical school, all Consultant Psychiatrists had the necessary 
qualifications to study undergraduate mathematics.  The potential benefit of quantitative 
methods for patients should be introduced early in undergraduate medical training. 
 
Conclusions 
Mental illness and substance use disorders are the leading cause of disability world-wide, 
suicide is a leading cause of death in young adults, and severe and enduring mental illness is 
associated with a reduction in lifespan of about a decade.  Despite this, clinical practice in 
psychiatry has not changed fundamentally in over half a century.   There is good evidence 
that clinically useful individual patient predictions of diagnosis, clinical outcome and 
treatment response, can be made using neuroscience techniques.  This predictive approach 
does not depend on understanding psychiatric nosology or illness mechanisms. 
      Given the remarkable disability and mortality associated with mental illness and 
addictions, it is crucial to invest more in UK biomedical research and clinical practice 
implementation.  However without organised stakeholder support influencing politicians 
and funding leaders, not much is likely to change.  Currently, the area of UK psychiatry that 
seems most likely to develop and implement these new clinical techniques is old age 
psychiatry.  We hope this will expand to include mental illness and addictions when the 
potential benefits become better known.  
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Fig. 1 Group level significance, univariate and multivariate prediction. (a) Representation of the distribution 
of a single variable, such as hippocampal volume, for controls with mean (mc) volume and patients with a 
smaller mean (mp) volume. Assuming a hippocampal volume reduction in MDD with Cohen’s d=0.14 and 
8,921 subjects,12 the two group t-test (MDD vs control) difference in volume is highly significant (p=3.8e-
6). If a cut-off (cut) is defined which balances sensitivity and specificity, then the true positive (TP), false 
positive (FP), true negative (TN) and false negative (FN) rates can be calculated, indicating very low 
diagnostic sensitivity, specificity and accuracy of 52%, 53% and 52% respectively (50% random). (b) Two 
variables are measured for each subject, both of which have highly overlapping patient and control 
distributions. Each point represents a patient (black) or control (grey) subject. Machine learning, such as a 
support vector machine, identifies the maximal distance ‘d’ hyperplane separating the two groups during 
training. When data from a new subject becomes available, then whichever side of the hyperplane the new 
data appears, defines the prediction (e.g. MDD vs control). Only two predictor variables are shown for 
clarity, normally a large number of variables are used.  
Page 14 of 14
Cambridge University Press
BJPsych
For Peer Review
 
 
 
180x262mm (300 x 300 DPI)  
 
 
Page 15 of 14
Cambridge University Press
BJPsych
